🏥 Health
6d ago
Drug Combo for Lung Cancer Beats Pembrolizumab in First-Line Trial
Source ↗
👁 2
💬 0
(MedPage Today) -- CHICAGO -- Adding an investigational TROP2-targeted antibody-drug conjugate (ADC) to first-line immunotherapy for PD-L1-positive non-small cell lung cancer (NSCLC) reduced the risk of disease progression and may have improved...
Comments (0)